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Abstract
Research has demonstrated that hepatitis C (HCV) genotype distribution varies geographically and
demographically. This exploratory study examines HCV viremia, viral concentration, and
genotype distribution among anti-HCV positive, rural Appalachian nonmedical prescription drug
users. The study population was randomly selected from a pool of 200 anti-HCV positive
participants in a longitudinal study. Those randomly chosen were representative of the overall
pool in terms of demographics, drug use, and other risk behaviors. Participants were tested
serologically for HCV RNA, viral concentration, and genotype, and interview-administered
questionnaires examined behavioral and demographic characteristics. Of the 81 participants, 69%
tested RNA positive, 59% of which had viral loads exceeding 800,000 IU/mL. Approximately
66% of the RNA positive sample had genotype 1a; types 2b (16%) and 3a (13%) were less
common. RNA positive participants were not significantly different than RNA negative
participants demographically or behaviorally. Likewise, with the exception of education, genotype
1 participants were not significantly different than those with genotype 2 or 3. The prevalence of
active HCV infection highlights a need for prevention and treatment in this population. However,
the predominance of genotype 1 may present challenges due to its association with decreased
responsiveness to drug treatment, although the novel class of direct-acting antivirals such as
telaprevir and boceprevir offer new hope in this regard. The prevalence of genotype 1 may also
foreshadow heightened burden of hepatocellular carcinoma and elevated healthcare expenditures.
More research is needed to characterize HCV infection and genotype in this population.
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An estimated 3.2 million people in the US have chronic hepatitis C (HCV) infection, making
the pathogen the most common chronic blood-borne infection nationwide [Armstrong et al.,
2006]. Chronic HCV infection is a strong risk factor for the development of hepatocellular
carcinoma (HCC) [Colombo, 1999; Di Bisceglie, 1997; El-Serag and Mason, 2000; Thomas
and Seeff, 2005; Tsai et al., 1994] and cirrhosis of the liver [Thomas and Seeff, 2005]. The
progression of chronic HCV infection to serious liver disease is associated with age at
infection, male gender, immunosuppression, coinfection with HIV and hepatitis B virus
(HBV), and heavy alcohol intake [Thomas and Seeff, 2005].
There has been considerable debate regarding differences in pathogenicity and
hepatocarcinogenic potential of the various genotypes of HCV [e.g., Brechot, 1997; Bruno
et al., 1997; Bruno et al., 2007; Fattovich et al., 2004; Romeo et al., 1996; Sangiovanni &
Iavarone, 2008]. A recent meta-analysis of 21 age-corrected studies by Raimondi and
colleagues (2009) found increased risk of HCC in patients infected with genotype 1b, with
or without the presence of cirrhosis. Unfortunately, many of the studies included are from
geographical regions where genotype 1b predominates [Zein, 2000], and there are few
studies from HCV genotype 1a-predominant areas for comparison. Other studies have found
similar associations with HCC risk for both 1a and 1b subtypes within genotype 1 [Lee et
al., 2010; Tanaka & Hirohata, 1998; Zein et al., 1996; Zekri et al., 2000;], and even within
genotypes 2a [Han et al., 1997], 3a [Khan et al., 2009], and 4, with no difference between
subtypes [Ryu et al., 2009]. However, differences in relative risk reported in some studies
may be due to regional differences in genotype prevalence [Haydon et al., 1997; Mangia,
1997; Reid, 1999; Widell, 2000] and/or a cohort effect reflecting confounding age-related
and disease-progression variables [Di Tomasso et al., 2003; Lopez-Labrador et al., 1997;
Sartori et al., 2006]. Thus while the association between HCV genotype and the severity of
hepatic disease remains controversial, a majority of studies have found both subtypes within
genotype 1 to confer heightened risk of histopathological damage, concomitant progression
to HCC, and to a lesser extent, persistence of infection [Lehmann et al., 2004; Mehta et al.,
2002; Strasfeld et al., 2003a; Thomas et al., 2000; Villano et al., 1999].
In addition, those infected with HCV genotype 1 have also shown a diminished sustained
virologic response (SVR) to treatment with pegylated interferon-alpha (IFN-α) and
ribavirin, and these patients typically require a longer duration and a greater dosage of
combination therapy than do genotypes 2 and 3 [Manns et al., 2001; National Digestive
Diseases Information Clearinghouse (NDDIC), 2006; Poynard et al., 1998; Scott and Perry,
2002; Shepherd et al., 2004; Zein et al., 1996]. However, the new class of direct-acting
antivirals (DAAs) such as telaprevir and boceprevir have enabled a new “triple-therapy”
standard-of-care combining the new agents with standard IFN-α and ribavirin
therapy[Pawlotsky, 2011; Nelson, 2011]. Several studies have demonstrated improved
outcomes and shortened treatment regimes amongst individuals infected with genotype 1 in
both previously treated [Bacon et al., 2001; McHutchison, 2010] and untreated [Poordad et
al., 2011] cases, with an increase in SVR from 50% up to 70% [Asselah et al., 2010] and
even raising the possibility of interferon-free treatment options in the future [Dore et al.,
2011]. However, as with ribavirin and IFN-α, DAA therapy is not without its own threat of
adverse effects and resistance mutations [Fonseca-Coronado et al., 2011; Fried, 2011;
Khalid & Bacon, 2011], and the high cost could present a barrier to uninsured and
underinsured patients such as injection drug users (IDUs), who already tend to have
significant barriers to HCV treatment [Grebely et al., 2008; Swan et al., 2010].
Despite earlier recommendations to avoid treating only former and recovering IDUs infected
with HCV [National Institutes of Health (NIH), 1997], recent evidence suggests that
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standard HCV treatment can be successful among active IDUs [e.g. Dore et al., 2010;
Hellard et al., 2009; Manolakopoulos et al., 2010; Papadopoulos et al., 2010; Schulte et al.,
2010;]. However, in addition to HCV genotype, HCV viral concentration can also impact
treatment success. For example, previous evidence has suggested that patients with high
HCV RNA concentrations are less responsive to pegylated interferon-alpha (IFN-α) and
ribavirin combination therapy [Lam, 1999] and to IFN-α and ribavirin combination therapy
[Munir et al., 2010]. Other studies have indicated that patients with high RNA levels,
particularly those who are non-responders to other treatment regimens, may be more
responsive to consensus interferon [Alberti, 1999; Witthöft, 2008; Witthöft et al., 2007],
though there does appear to be some variability in cost effectiveness depending on the
intensity of treatment [Sjogren et al., 2007]. The NDDIC suggests that a HCV viral
concentration of less than 800,000 IU/mL can determine a better response to IFN-α and
ribavirin treatments [NDDIC, 2006].
In addition to the clinical and epidemiological implications, HCV is associated with great
economic burden in terms of increased absence from job-related activities and productivity,
as well as increased healthcare service utilization and healthcare costs [Davis et al., 2011;
DiBonaventura et al., 2010; Su et al., 2010]. In fact, Su and colleagues (2010) found that
healthcare-related costs for HCV-infected individuals can be over $8000 per year more than
that for non-infected individuals. A study by Grant and colleagues (2005) examining trends
in healthcare service utilization for HCV infection in the US found that costs increase
considerably with the aging of the HCV-infected population and with HCV disease
progression. At this juncture, the authors note that, “as patients continue to age and disease
burden progresses, suboptimal decisions regarding HCV treatments will bring increasing
opportunity costs for the health care system and society” [Grant et al., 2005, p. 1406].
Moreover, a growing body of evidence suggests that decision-making regarding HCV
treatment and its cost-effectiveness will be influenced by HCV RNA concentration and
genotype. Higher HCV viral load and infection with genotype 1 have negative impacts on
the cost-effectiveness of various treatments regimens [Hartwell et al., 2011; Salomon et al.,
2003; Shepherd et al., 2004; Sullivan et al., 2004; Wong et al., 1998; Yeh et al., 2007] and
of early intervention strategies [Shepherd et al., 2007]. The issue is complicated further in
the active IDU population, in which reinfection following treatment is a serious concern,
although the frequency of reinfection in IDUs following SVR to drug therapy is low
[Grebely et al., 2010]. Furthermore, using mathematical modeling, Martin and colleagues
(2011) have shown that treating active IDUs is more cost-effective than leaving them
untreated, provided the prevalence of chronic HCV infection is under 60%.
Substantial geographic and demographic variation can exist in the distribution of HCV
genotypes [Blatt et al., 2000; Zein and Rakela, 1996]. HCV genotypes 1a/1b, and to a lesser
degree 2b and 3a, are predominant in the US population [Nainan et al., 2006; Zein, 2000;
Zein and Rakela, 1996], and HCV genotypes and subtypes within the country vary
according to ethnicity and age. In a nationally representative sample, increased age and non-
Hispanic black race/ethnicity were associated with an increased likelihood of infection with
HCV genotype 1b [Nainan et al., 2006]. Research examining HCV genotype distribution has
been used for various purposes, including the identification of populations’ origin of HCV
infection [Panduro et al., 2010; Spada et al., 2008], examination of historical trends in
characteristics of HCV infection [Magiorkinis et al., 2009], and making inferences regarding
routes of HCV transmission [van den Berg et al., 2009; Zein, 2000; Zhou et al., 2009]. In a
review of the HCV literature on drug users published between 1989 and 2006, Stern et al.
(2008) identified 123 studies which reported genotype distribution [Stern et al., 2008], and
in the past two to three years, there has been growing recognition of the value of descriptive
studies examining HCV genotype distribution in drug using populations [e.g. Lee et al.; Liao
et al., 2011; Micalessi et al., 2008; Sereno et al., 2009; Viazov et al., 2010; Zhou et al.,
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2009]. However, nearly all of the existing studies to date have been conducted either outside
of the U.S. or in urban populations.
In light of the epidemiologic, clinical, and economic implications of HCV genotypes and
their uneven dispersion within certain populations, more research is needed to elucidate the
genotype distribution and prevalence of HCV viremia in high-risk, HCV-exposed groups
from under-resourced settings in the US. As of 2007, Kentucky had the 7th highest HCV
incidence rate in the nation [Daniels et al., 2009], yet the HCV burden has been largely
uncharacterized. Given the implications of HCV viremia and genotype on treatment cost-
effectiveness, this gap in knowledge can present a major barrier to the planning of HCV
intervention strategies in the state’s economically distressed region of Appalachia
[Appalachian Regional Commission (ARC), 2011], where cost-effectiveness is a paramount
consideration in healthcare system decision-making. Efforts to understand the HCV burden
in Appalachia are made more relevant by the region’s distinguishing burden of drug use.
Unlike other populations that have been the focus of other HCV-related studies on drug
users, Appalachia drug users are predominantly abusing prescription drugs [Drug
Enforcement Agency, 2002; Havens et al., 2007; Young et al., in press], and have distinctive
profiles of HCV-related drug risk behavior [Havens et al., 2007; Young and Havens, 2011;
Young et al., 2010].
There is emerging evidence that demonstrates that IDUs in Appalachia are indeed much
different than IDUs in other populations in terms of their risk behaviors and drug use
characteristics. In fact, studies have demonstrated that drug users in Appalachia have
substantially different trajectories of drug use than residents of urban areas in Kentucky,
with significantly earlier ages of onset for use of oxycodone, hydrocodone, benzodiazepines,
cocaine, and crack. Adjusting for age, gender, and race, the rural drug users had higher odds
of lifetime and recent nonmedical prescription opioid use (specifically methadone,
OxyContin®, and oxycodone) and had higher odds of lifetime cocaine and crack use [Young
et al., in press]; the latter of which have been identified to be associated with HCV RNA
concentration [Operskalski et al., 2008]. Evidence also demonstrates that compared an urban
sample of drug users in the state, rural Appalachian drug users are more likely to use
alternative routes of administration (e.g. snorting and injecting) for many drugs. In fact,
among the Appalachian participants in one study, snorting was the most frequent route of
administration for hydrocodone, methadone, OxyContin®, and oxycodone, and injection was
most common for hydromorphone and morphine [Young et al., 2010]. These findings were
corroborated by another study which demonstrated that prescription opiate misuse and
injection drug use was higher among rural Appalachian probationers compared to their
urban counterparts [Havens et al., 2007]. The prevalence of use of alternative routes of
administration by drug users in the Appalachian region increases their risk for acquiring
HCV and underscores the importance of examining HCV in the population.
A study based on recent retrospective survival analyses of drug users in Appalachia found
that this population differs drastically from those involved in other studies of IDUs, and that
nonmedical prescription opioid use may be the differentiating factor. OxyContin® was
involved in nearly as many initiations to injection (48%) as were stimulants, other
prescription opioids, and heroin combined. The rate from which users transitioned from first
OxyContin® use to initiation of injection with OxyContin® was extremely fast, just 3 years
on average. The sample’s nonmedical prescription drug use played a significant role in their
hazard for initiating injection, with five prescription drugs (benzodiazepines, illicit
methadone, oxycodone, OxyContin® and other opiates) associated with an increased hazard
for transitioning, adjusting for demographics characteristics [Young and Havens, in press].
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Historically and culturally, there are also reasons to believe that the epidemiological
characteristics of HCV in Appalachia could differ from that of other regions in the US. For
example, molecular evidence has demonstrated that HCV type 1 was likely first introduced
into the US in approximately 1909 and more widely disseminated throughout the US
population in the 1960’s [Mizokami et al., 2006; Tanaka et al., 2002]. During the diffusion
of HCV in the 1960’s, the Appalachian region was becoming increasingly recognized as
being heavily isolated and distinct from other populations in the US, though efforts were
underway to “integrate” and “modernize” its residents [Photiadis and Schwarzweller, 1970;
Whisnant, 1980]. The degree to which Appalachian residents were isolated from larger
society has been debated [Lewis and Billings, 1997], and the extent to which the isolation
continues is not well-established and likely highly variable across communities.
Nevertheless, there continues to be sociological and demographic evidence that suggests the
region experiences extensive out-migration, but little in-migration of new residents [ARC,
2011; Bell, 2009]. The role that Appalachia’s regional isolation and its unique patterns of
drug use play in influencing the profile of HCV are speculative, but certainly cause for
further investigation. Thus, the purpose of this exploratory study was to (1) assess the
prevalence of HCV viremia (i.e. HCV RNA positivity), (2) examine quantitatively the HCV
RNA viral concentration, and (3) determine the HCV genotype distribution among a random
sample of anti-HCV positive drug users in a rural Appalachian region of Kentucky.




The study sample was randomly-selected from a larger cohort of anti-HCV positive rural
Appalachian prescription opioid users involved in the Social Networks among Appalachian
People (SNAP) study (N=436). The SNAP study is a longitudinal cohort study seeking to
determine the prevalence and incidence of HCV, HIV and herpes simplex-2 virus in the
context of rural drug and sex social networks in order to determine the potential for disease
transmission in this largely understudied population of illicit prescription drug users. A
storefront location in a rural Appalachian town of approximately 5000 residents was used
for the SNAP study’s participant recruitment and interviews. Participants were recruited
using respondent-driven sampling, which is often the most appropriate sampling technique
for hidden populations such as drug users [Heckathorn, 1997; Heckathorn, 2002; Wang et
al., 2007]. Study recruitment began in November, 2008 and was completed in August, 2010.
Eligibility criteria for the study included those who were at least 18 years of age, were
residents of an Appalachian county and had used at least one of the following drugs to get
high in the prior 30 day period: prescription opioids, heroin, crack/cocaine or
methamphetamine. Probing participants to respond only about drugs they used ‘to get high’
is a lay-language, and more specific adaptation of the language used by the Substance Abuse
and Mental Health Services Administration (SAMHSA) in the National Survey of Drug Use
and Health, who defines nonmedical prescription drug use as “use of at least one
[prescription-type psychotherapeutic] without a prescription belonging to the respondent, or
use that occurred simply for the experience or feeling the drug caused [Substance Abuse and
Mental Health Services Administration (SAMHSA), 2008].” It should be noted that while
the eligibility criteria stated they could have used one of the four aforementioned substances,
100% of those screened and enrolled indicated they had used prescription opioids to get high
in the 30 days prior to the screening. An interviewer-administered questionnaire was utilized
to determine self-reported behaviors. Data were entered by the interviewers directly onto a
touch screen laptop loaded with computer-assisted personal interviewing software.
Participants were compensated $50 the baseline and follow-up interviews and $25 to
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participate in the genotyping study. The Institutional Review Board at the University of
Kentucky approved the protocol and informed consent was obtained from all participants.
At the baseline visit, all participants consented to antibody testing for hepatitis C using the
Home Access test for HCV antibody, which uses a third-generation enzyme immunoassay
on dried blood spot specimens collected by finger-stick (sensitivity: 98.2%; specificity
99.6%) and has demonstrated accuracy [O’Brien et al., 2001]. The baseline prevalence of
anti-HCV was 45.9% (n=200). Tests for HIV and HSV-2 were conducted and currently, no
participants were HIV-positive and the baseline seroprevalence for HSV-2 is low (11.5%).
Prior to undergoing testing for anti-HCV, HIV and HSV-2, participants were provided with
pre-test counseling that included a description of the test, risk factors for HCV, HIV and
HSV-2 and the potential test results. After the sample was provided for HCV testing, the test
was sent to the reference laboratory for testing using an anonymous PIN number so that only
study staff was aware of the results. Results were returned via PIN number within
approximately 2 weeks. Participants were asked to return at that time for their test results
and were provided with post-test counseling that was tailored to their study result. For
example, for those who were anti-HCV positive, counseling was given on how to prevent
transmission to others and information was provided on treatment referrals in the area.
Rapid testing was conducted for HIV and HSV-2 and results were provided during the
baseline visit.
The following procedures were undertaken to ascertain the final sample of 81 participants
included in this analysis. First, all participants who were anti-HCV positive at baseline
(n=200) were added to a SPSS database. In an attempt to meet the participation goal of at
least 100 participants submitting samples, the random selection procedure in SPSS was used
to select 160 individuals for recruitment. Recruitment was conducted through phone calls
and mailed letters. Of those randomly selected, 23 were unable to participate either due to
incarceration out of the area, having moved out of the area, hospitalization, or traveling for
work. Of the remaining 137, 84 (61.3%) participated in the study. Non-participants (n=53)
included 36 who were unable to be contacted in the short time frame provided to complete
the study, one who lacked transportation to the study site, one whose occupation conflicted
with the study schedule, seven who confirmed but did not show, and seven for whom a
reason was not specified. Participants who presented at the study site completed informed
consent and the blood draw and were compensated $25 for their time. From June to July of
2010, 76 individuals presented at the study site to participate and 8 participated while
incarcerated in the local jail.
Serological tests for detection of HCV RNA and HCV genotype
Phlebotomists were unable to acquire samples from 3 of the 84 participants, resulting in an
overall sample size of 81. Approximately 17mL of blood was drawn from each participant
and, following a standard protocol, plasma was separated for HCV RNA testing. Plasma was
frozen immediately after centrifugation and was shipped frozen within 48 hours of
collection to the performing laboratory (Quest Diagnostics Nichols Institute – Chantilly,
VA).
The presence and quantitation of HCV RNA was determined through COBAS® Ampliprep/
COBAS® TaqMan® HCV test kit (Roche Molecular Systems, Inc) using real-time
polymerase chain reaction (PCR), transcription-mediated amplification (TMA), and multi-
probe reverse hybridization of the 5′ untranslated region (5′ UTR) of the HCV genome.
Results were reported in international units per milliliter (IU/mL). HCV RNA-positive
specimens (RNA concentration > 5 IU/mL) then underwent testing for HCV genotype and
subtype using HCV RNA Genotype, LiPA™ through reverse transcription and PCR (RT-
PCR) and reverse hybridization (Line Probe) of the 5′ UTR and core region of the HCV
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genome. Genotypes and subtypes detectable by this test include 1, 1a, 1b, 2, 2a/2c, 2b, 3, 3a,
3b, 3c, 4, 4a, 4b, 4c/4d, 4e, 4f, 4h, 5a, and 6a.
Nearly all specimens were of adequate quality and quantity for testing; however, the
laboratory was unable to conduct genotyping on one sample due to a low RNA
concentration and unable to differentiate HCV subtypes for one other. Thus, the total sample
sizes were as follows: HCV RNA (n=81) and HCV genotype (n=80). Participants whose
specimen was inadequate for testing were invited to return for re-testing, though none did.
An IRB-approved post-test counseling protocol was administered to participants for their
HCV RNA and HCV genotype results.
Assessment of demographic and behavioral correlates
At participants’ baseline assessment, two true/false items were included to examine
respondents’ knowledge of the transmissibility of HCV through the sharing of needles and
syringes and other injection equipment. Participants’ HCV transmission knowledge and their
demographic characteristics (see Table 1) were based on their baseline assessment in the
study, while behavioral characteristics were extracted from their most recently completed
interview (i.e. baseline, 6-month, 12-month, or 18-month interview). The average time
which had elapsed between participants’ most recent interview date and the date of their
blood draw was 51.7 days (SD 41.1; range: 18 – 140).
Statistical Analysis
The randomly selected sample’s representativeness of the pool of anti-HCV positive
participants was assessed through a series of chi-square tests and independent samples t-
tests. Demographic and behavioral correlates to HCV RNA positivity and for infection with
HCV genotype 1 versus genotypes 2 and 3 were examined through chi-square tests and
independent samples t-tests. Significance on all tests was defined as p<.05.
Results
Sample characteristics
Table 1 provides a demographic description of study participants (n=81). The sample was
representative of the overall anti-HCV positive pool of individuals (n=200) from which they
were drawn. The eighty-one participants did not significantly differ (p<.05) from those who
did not participate or who were not randomly selected to the study in terms of demographic
characteristics (gender, age, education, insurance status), health (self-reported health status,
lifetime number of hospitalizations), lifetime number of incarcerations, or HCV risk
behaviors (ever having injected drugs, ever having shared equipment for snorting drugs, and
ever having received a blood transfusion). The mean age of participants was 35 years (SD
8.3; range 21–53), the vast majority were white (95%) and nearly 60% were male. Factors
which could inhibit ability to seek care were common; 38% lacked access to transportation,
36% were unemployed, and 63% were uninsured. Nearly all participants were aware that
HCV was transmitted by sharing works (99%) and by sharing needles and syringes (100%).
The majority (86%) had a lifetime history of incarceration and 12% had been incarcerated
within the last 30 days. Only 56% had a history of drug abuse treatment.
Table 2 describes behavioral characteristics of the sample. Most participants had a history of
injection drug use (95%) and of sharing equipment to snort drugs (96%). Over half had
engaged in injection drug use within the last 30 days (51%). Between 11–20% of the sample
had been involved in some form of recent (<6 months) receptive and/or distributive syringe
sharing. Just less than 28% had used alcohol to intoxication within the last 30 days.
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Sixty-nine percent (n = 56) of the sample (which is anti-HCV positive) were positive for
HCV RNA. Figure 1 shows the distribution of HCV RNA concentrations for those testing
positive for HCV RNA. The HCV RNA concentration ranged from 23 IU/mL to 1.95 × 107
IU/mL, with a median of 9.93 × 105 IU/mL. The viral load for 33 (59%) of the HCV RNA
positive participants exceeded what is commonly considered a “low level” of HCV RNA (<
800,000 IU/mL) [NDDIC, 2006].
As shown in Table 1, HCV RNA positive participants were no different than their HCV
RNA negative counterparts in terms of demographic characteristics, HCV knowledge, self-
reported health status, lifetime hospitalizations, drug abuse treatment history, or lifetime and
recent incarceration. Table 2 provides a description of lifetime and recent behavioral
characteristics of the overall sample and of those who tested positive for HCV RNA. HCV
RNA positive participants were not significantly different than HCV RNA negative
participants in regard to their history of blood transfusion, lifetime and recent injection drug
use, or needle- and equipment-sharing behaviors. However, an association between RNA
positivity and injection drug use in the past 6 months neared significance (OR: 2.40, 95%
CI: 0.89 – 6.48; p=.086).
Figure 2 displays the genotype distribution for the sample. Among the 56 people who tested
positive for HCV RNA, HCV genotype 1a was most common (n=36, 65.5%), followed by
2b (n=9, 16.4%), and 3a (n=7, 12.7%). Two participants had dual infection with
heterologous HCV genotypes (1a/2b and 2b/3a), another had genotype 2 but subtype was
unable to be specified, and one participant had a RNA concentration too low to allow
genotyping. The HCV RNA concentration for participants with HCV genotype 1 did not
differ significantly from participants with genotypes 2 or 3 (p=.366). Participants with HCV
genotype 1 (which included hybridized type 1a/2b) were compared to those infected by
types 2 and 3 in terms of the demographic or lifetime behavioral characteristics listed in
Table 2. Participants who had graduated from high school were more likely to have HCV
genotype 1 than were participants who were not high school graduates (OR: 3.41, 95% CI:
1.01 – 11.55, p = .04). None of the other correlates examined had a statistically significant
association with genotype (data not shown).
Discussion
Among a random sample of anti-HCV positive prescription drug users drawn from a
longitudinal cohort study in Appalachia, the majority (69%) had active HCV infection. HCV
RNA positive participants were more likely to have a history of blood transfusion and more
likely to have injected drugs in the past 6 months and past 30 days. Significantly more
participants who were HCV RNA positive were white and uninsured than those who were
HCV RNA negative. HCV genotype 1a was detected in 66% of the HCV RNA positive
sample, while types 2b (16%) and 3a (13%) were less common.
The sample’s genotype distribution and RNA status have clinical implications. The most
prevalent HCV genotype in the sample, type 1, is less responsive to treatment, requires a
longer duration and higher dosage of combination therapy [Manns et al., 2001; NDDIC,
2006; Poynard et al., 1998; Scott and Perry, 2002; Zein and Rakela, 1996], and has potential
association with higher RNA levels and decreased likelihood of spontaneous clearance of
the virus [Berger et al., 1996; Kobayashi et al., 1996]. Also, in the majority of studies HCV
genotypes 1a and 1b seem to be more strongly associated with HCC than genotypes 2 and 3
[Raimondi et al., 2009; Tanaka & Hirohata, 1998; Zein et al., 1996;]. The proportion of
HCV-positive individuals who would require a long duration of treatment could present an
especially difficult situation in rural Appalachia, given marked health and economic
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disparities and barriers in access to care. The sample’s high RNA concentration may also
have implications for treatment [NDDIC, 2006] and prognosis [Hisada et al., 2005]. Ability
to extrapolate from the RNA concentration data is limited by the study’s cross-sectional
design, but it warrants mention that the RNA concentration for 59% of the sample exceeded
the range which usually determines a better response to peginterferon and ribavirin
treatments (< 800,000 IU/mL) [NDDIC, 2006]. However, new direct acting antivirals
boceprevir and telaprevir may mitigate some of the efficacy lost due to heightened viral load
in genotype 1-infected individuals [Asselah, 2010; Dore et al., 2011; Nelson, 2011].
The median viral concentration in this sample is nearly double that found other recent
studies of injection and non-IDUs [Schulte et al., 2010; Strasfeld et al., 2003a], similar to
that found in others [Boodram et al., 2011; Hisada et al., 2005], and lower than that found in
HIV co-infected cohorts [Obermeier et al., 2011]. Given the prevalence of high risk
behavior in this sample, the findings regarding elevated RNA concentration are not
unexpected; previous research has found that HCV viral concentration is positively
associated with risky drug use behaviors, including lifetime cocaine, marijuana,
amphetamine, or heroin use [Operskalski et al., 2008] and frequency of sharing unclean
syringes [Boodram et al., 2011]. The high viral concentration is concerning not only given
participants’ continued syringe sharing, but also given the prevalence of straw sharing
(96%). There is limited evidence to suggest that drug users with high HCV viral loads can
have detectable levels of HCV RNA in nasal secretions, which could have consequences for
HCV transmissibility through the sharing of straws [McMahon et al., 2004] and other drug
preparation equipment [Hagan et al., 2001].
The serological profile of this sample of Appalachian drug users, in some respects, mirrors
that of the US general population, and in other ways, is unique. The proportion of anti-HCV
positive individuals who tested positive for HCV RNA in our study (69%) was less than that
found in a nationally-representative sample (78%) [Nainan et al., 2006]. However, the
samples were similar in terms of HCV genotype. Among white, non-Hispanic individuals in
the national study, the weighted percentage of HCV RNA positive individuals infected with
genotype 1 was 70%, comparable to the prevalence of 66% reported in this study [Nainan et
al., 2006]. Similarly, the prevalence of genotypes 1, 2, and 3 in this study were comparable
to that found in samples from a large cohort of chronic HCV patients [Blatt et al., 2000]. In
terms of subtype, the present study found a higher percentage of individuals infected with
type 1a than did the national study or large clinic-based study (66% versus 52% and 39%,
respectively) and a lower percentage infected with type 1b (0% versus 27% and 30%,
respectively) [Blatt et al., 2000; Nainan et al., 2006]. In the present study, participants with
HCV genotype 1 were more likely to have graduated from high school than participants with
genotypes 2 and 3, though the difference was marginally significant (p=.04) and the
confidence interval was wide. This association between education and genotype remained
statistically significant even after controlling for age. The study’s finding that HCV
genotype 1 was associated with higher educational status is curious. To explore explanations
for the association of education and genotype, demographic and behavioral correlates to
education were examined. Educational status was positively associated with age (p=.018),
but not associated with any other demographic or behavioral variables (data not shown).
When analysis of the association between education and genotype was adjusted for age, the
association between education and genotype remained statistically significant (OR: 3.87,
95% CI: 1.03 – 14.53). To our knowledge, no other study to date has reported an association
between education and genotype, thus further research is necessary to verify and explore this
potential association.
The disparity in the subtype findings may be attributed to differences in racial composition
of the samples, as type 1b is more common among non-Hispanic blacks. The differences
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may also be attributable to the likely infection route for the source populations. Genotypes
1a and 3a are more common among those with a history of injection drug use [Serra et al.,
2003; Zein, 2000; Zeuzem et al., 1996], a behavior which characterizes 95% of our sample.
Some research has suggested that genotype may be correlated with year of infection
[Chlabicz et al., 2008; Pybus et al., 2001; Zeuzem et al., 1996; Zhou et al., 2009], or
correspondingly, with the year of the genotype’s introduction into the population [Gérard et
al., 2005; Katsoulidou et al., 2006]. The vast majority of participants began injecting drugs
within the last 15 years, over half between 1995 and 2005, and over a quarter since 2005
(data not shown). The exploratory nature of this study precludes our ability to make
inference regarding the mechanisms that produced the identified genotype distribution.
However, further research could explore whether the relatively recent initiation of drug-
related risk behavior within the sample corresponds with the national, temporal shift in
prevalence from genotype 1b to 1a [Nainan et al., 2006].
This study not only contributes to epidemiologic knowledge about HCV in rural Appalachia,
but also offers insight for intervention. An alarming proportion of individuals with active
HCV infection were engaging in risk behaviors which could promulgate the infection
through the study population. Among those with active infection, one in seven had engaged
in recent distributive needle sharing (i.e. had sold, returned, or given away a needle after
using it). On the flipside, among individuals without active infection (i.e. HCV RNA
negative), nearly one in eight had engaged in recent receptive needle sharing. This
population’s involvement in risk behavior is likely not attributable to inadequate knowledge
about HCV transmission. In fact, 100% of the sample was aware that HCV could be
transmitted through sharing needles and syringes and 99% was aware HCV could be
transmitted through sharing other injection equipment.
These findings demonstrate a need for behavioral, clinical, and structural interventions to
prevent secondary transmission and increase access to treatment. Intervention may be
particularly difficult in rural Appalachia due to a lack of resources. Previous research has
shown that syringe exchange programs (SEPs) can substantially decrease risk behavior [Des
Jarlais et al., 2005; NIH, 1997, 2002], HCV prevalence [van den Berg et al., 2007], and
HCV incidence when coupled with drug treatment [Des Jarlais et al., 2009]. SEPs also
provide a strategy for providing drug users with condoms, referrals to substance abuse
treatment, and HCV testing and counseling [NIH, 1997, 2002]. Nationally, the
implementation of SEPs is difficult due to legal and regulatory restrictions; Kentucky is no
exception. While Kentucky does not directly prohibit the establishment of SEPs, statutes
regulate the sale and disposal of hypodermic syringes and needles and criminalize the
possession of drug paraphernalia [Kentucky Legislative Research Commission (KLRC),
1992; KLRC, 2005]. In addition to regulatory barriers, economic circumstances may impede
the implementation of a SEP in the region. According to the Centers for Disease Control and
Prevention (CDC), 28% of existing SEPs operate on a budget of less than $25,000, 37%
operate on a budget between $25,000 and $100,000, and 35% on budgets greater than
$100,000 [Centers for Disease Control and Prevention (CDC), 2005]. Given the impact of
chronic HCV infection on quality of life [Bernstein et al., 2002; Foster et al., 1998] and
healthcare costs [Davis et al., 2011; DiBonaventura et al., 2010; Su et al., 2010], the cost-
effectiveness of a SEP in the region is worth consideration. In lieu of SEPs, behavioral and
clinical interventions may be applicable. Peer-driven and other behavioral interventions
could also be considered as a way to reduce HCV risk behavior in this population [Garfein
et al., 2007; Latka et al., 2008; Sacks-Davis et al., 2011]. Programs and funding to improve
residents’ access to health care and to drug treatment also could help to prevent and/or
mitigate the long-term consequences of HCV infection. Clinical interventions, however,
must be coupled with strategies which address structural barriers, such as lack of
transportation.
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While the study provides foresight into possibilities for intervention in this population, it is
not without limitations. The study’s reliance on self-report subjects the data to potential
information bias, which if present, would likely bias the results toward the null hypothesis
and would make the reported findings more conservative than if no bias existed. Like other
recent descriptive studies regarding HCV genotype distribution [e.g. Lee et al., 2010; Liao et
al., 2011; Micalessi et al., 2008; Sereno et al., 2009; Viazov et al., 2010; Zhou et al., 2009],
the study’s sample size and cross-sectional design present limitations. Though the sample
was drawn randomly from and was representative of a larger pool of HCV antibody positive
drug users, the sample’s size and homogeny in terms of behavioral and demographic
characteristics limits the power to distinguish correlates to HCV RNA positivity and
genotype. The cross-sectional design also precludes the ability to make causal inferences
and to draw conclusions about dynamics of fluctuation in viral concentration, as well as
reinfection, coinfection, and superinfection. The inability of the study to provide more
detailed phylogenetic analysis also limits inference about the dynamics of transmission.
Conclusion
Despite limitations, this study provides important insights into a high-risk, under-studied,
rural population. The prevalence of active HCV infection and distribution of certain
genotypes in this sample of HCV-exposed drug users highlight a need for primary and
secondary prevention strategies as well as interventions aimed at increasing access to
appropriate treatment. Though more research is needed to determine the underpinning
factors associated with HCV infection and subtype distribution within this population, it is
clear that a combination of structural, behavioral, and clinical intervention is necessary to
mitigate the consequences of HCV in this region with marked health disparities.
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